Business
Nemaura Develops Medical Grade SugarBEAT® Android App for Diabetes Management
Nemaura Develops Medical Grade SugarBEAT® Android App for Diabetes Management.
About this update from Nemaura Medical, Inc.
[{"type":"text","content":"\n \n Nemaura Medical Inc. (OTCQB: NMRD), a medical technology company focused \n on the development and commercialization of sugarBEAT®, a wireless \n adhesive skin-patch for adjunctive use by diabetics as a non-invasive \n and needle-free continuous glucose monitoring (CGM) system announced \n today that it has completed development of a medical grade app prepared \n and verified in accordance with ISO13485 quality systems and the \n appropriate medical devices directives, and designed to be used with the \n sugarBEAT® device or with glucose meters and strips to display glucose \n levels on users android mobile devices.\n \n \n The new app has been designed to display glucose trends, and Ambulatory \n Glucose Profiles (AGP), with users optionally able to input diet, \n medication and exercise information. Development of the iOS version of \n the app is also planned.\n \n \n SugarBEAT® consists of a disposable skin-patch connected to a \n rechargeable transmitter, and mobile app displaying glucose readings.\n \n \n A predecessor sugarBEAT® device has previously been granted CE approval. \n SugarBEAT® is due to complete clinical trials with anticipated launch in \n the UK later this year.\n \n \n About Nemaura Medical, Inc.\n \n \n Nemaura Medical is a medical technology company developing the wireless \n sugarBEAT® disposable adhesive skin-patch as a non-invasive, \n needle-free, pain-free and affordable continuous glucose monitoring \n (CGM) system for adjunctive use by diabetics. For more information, \n please visit www.nemauramedical.com.\n \n \n Cautionary Statement Regarding Forward Looking Statements\n \n \n The statements in this press release that are not historical facts, and \n may constitute forward-looking statements that are based on current \n expectations and are subject to risks and uncertainties that could cause \n actual future results to differ materially from those expressed or \n implied by such statements. Those risks and uncertainties include, but \n are not limited to, risks related to regulatory approvals and the \n success of Nemaura Medical’s ongoing studies, including the safety and \n efficacy of Nemaura Medical’s sugarBEAT® CGM system, the failure of \n future development and preliminary marketing efforts, Nemaura Medical’s \n ability to se...